The 10th International Conference on Oral Iron Chelators in the treatment of beta-thalassemia and other diseases and biomed meeting.
Development of oral iron (Fe) chelation therapy remains an important goal for the treatment of Fe-overload disease and perhaps other conditions. For many years, the major problem with Fe chelation therapy has been that the drug in clinical use. desferrioxamine (DFO), requires long sc. infusions (12-24 h day, 5-6 days per week). In addition, DFO is not orally effective, is highly expensive and does not easily permeate cell membranes to bind intracellular Fe pools. Obviously, the development of an orally effective and economical drug is vital. The recent 10th International Conference on Oral Iron Chelators (ICOC) discussed the latest findings in this challenging field. The conference was particularly focused to discuss recent investigations with the orally effective chelator, deferiprone (also) known as Li, DMHP or 1, 2-dimethylhydroxypyridone).
Richardson
D R
DR
The Heart Research Institute, Sydney, New South Wales, Australia. d.richardson@hri.org.au
D000284:Administration, Oral; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D017086:beta-Thalassemia / Q000188:drug therapy*
D007502:Iron Chelating Agents